Pfizer's (NYSE:PFE) stock up by 7.7% over the past three months. However, we decided to study the company's mixed-bag of ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

Biotech giant Bristol-Myers Squibb Company (BMY) is scheduled to report second-quarter 2025 results on July 31, before market ...

In light of this shifting landscape, investors seeking diversification would do well to consider three companies that stand out as prime potential beneficiaries of a rotation from tech to healthcare: ...

These five blue-chip dividend stocks have had a tough 2025 but are solid long-term buys for growth and income investors.

Pfizer saw a staggering increase in call options trading, with investors snapping up 539,824 contracts, marking a 286% jump ...

While you can't see Buffett's other seven high-yielding dividend stocks in Berkshire's filings, the company, in essence, has ...

Pfizer witnessed a dramatic 45.77% surge in trading volume, reaching a staggering 11.97 billion shares. Pfizer's stock price ...

Tariffs, and their potential detrimental impacts on vehicle affordability, company profits, global competitiveness, and ...